Aktuella utlysningar, vecka 23, 2021
Grants Office tipsar om aktuella anslag
Svenska och nordiska anslag
Research grants for prevention of animal testing – Forska Utan Djurförsök
These support research aimed at developing methods of biomedical risk assessments of chemicals, drugs and other products that can replace the use of animal testing. Grants are usually worth between approximately SEK 100,000 and 350,000 each.
Closing date: 30 June 2021
Research on kidney transplants – Stiftelsen Professor Lars-Erik Gelins Minnesfond
Stiftelsen Professor Lars-Erik Gelins Minnesfond inbjuder ansökningar om bidrag för forskning om njurtransplantationer. Dessa stöder vetenskapliga forsknings- och utvecklingsprojekt som rör njurtransplantationer och som främjar den aktiva uremivården, huvudsakligen med inriktning på njurtransplantationer. Forskningsprojekt som förväntas få klinisk betydelse inom en överskådlig framtid prioriteras. Projekt måste bedrivas vid institutioner i Sverige.
Closing date: 30 June 2021
Science & SciLifeLab Prize for Young Scientists
Science/AAAS and SciLifeLab, a coordinated effort of four universities, have joined forces in creating the Science & SciLifeLab Prize for Young Scientists. It is an extra encouragement to young scientists as they begin their scientific careers. Each year, the grand prize winner will receive a prize of US$30,000; each of the three category winners will receive US$10,000. The grand prize winning essay will be published in Science and essays from the three category winners will be published online.
The prize is presented in four categories: Cell and Molecular Biology; Ecology and Environment, Molecular Medicine, and, Genomics, Proteomics and Systems Biology approaches .
Applicants are to submit a 1000-word essay that is judged by an independent editorial team organized by the journal Science. Essays are judged on the quality of research and the applicants’ ability to articulate how their work would contribute to the scientific field.
Closing date: 15 July 2021
The Swedish Research Council (Vetenskapsrådet)
Project grant for research into post-COVID
The purpose of the project grant is to fund research into post-infectious conditions with remaining or late-onset symptoms following COVID-19 infection (post-COVID).
Project grant for research into societal security
The purpose of the grant is to strengthen Swedish research focused on societal security, such as climate changes, natural catastrophes, pandemics, military threats, terrorist attacks or destabilisation and disinformation campaigns.
Proof of concept within the infection area
The purpose of the grant is to bridge the gap between basic research and commercialisation of research results within the infection area. The proof of concept grant offers persons who are receiving or have received a grant from the Swedish Research Council the opportunity to further develop their research results.
Project grant within psychiatric research
The purpose of the grant is to support research into compulsory mental care and forensic psychiatry.
Project grant for research within primary care
The purpose is to give researchers the freedom to formulate their own research ideas, methods and implementation, and to solve a defined research task within a limited period of time.
Grant for research time within primary care
The purpose of the grant is to give persons within primary care the opportunity to conduct relevant research within the area general medicine, and to establish themselves as independent researchers in parallel with developing their professional competence.
Closing date: 17 August 2021
WASP and DDLS announce a joint call for research projects
The two largest research programs in Sweden, WASP (Wallenberg AI, Autonomous Systems and Software Program) and the SciLifeLab and Wallenberg National Program for Data-Driven Life Science (DDLS) (funded by the Knut and Alice Wallenberg Foundation) has now launched a joint call for bridging research projects, as a step towards the ultimate goal of solving ground-breaking research questions across disciplines. Projects should be led jointly by one faculty from WASP and one from DDLS. The DDLS faculty can be any researcher based at a Swedish university or the Museum of Natural History, conducting research with a data or computational angle within DDLS' four research areas (Cell and molecular biology, Evolution and biodiversity, Precision medicine and diagnostics and Epidemiology and infection biology).
Closing date: 1 September 2021
Doctoral grant in nursing – Svensk Sjuksköterskeförening
This aims to stimulate nursing research of high relevance and scientific quality as a basis for increased evidence-based use of clinical nursing for the benefit of patients and relatives. The grant is worth SEK 110,000.
Closing date: 3 September 2021
Postdoctoral fellowship programme for research in Japan: standard – Japan Society for the Promotion of Science
This supports young postdoctoral investigators in conducting research in cooperation with host researchers at Japanese universities and research institutions. Fellowships last for up to two years and provide airfare, a monthly maintenance allowance of JPY 362,000, a settling-in allowance of JPY 200,000 and travel insurance.
Closing date: 3 September 2021
Appropriate immunisation in patients with immune-mediated inflammatory conditions - Pfizer
Pfizer invites applications for its call on appropriate immunisation in patients with immune-mediated inflammatory conditions. This supports quality or process improvement projects, and medical education and patient awareness initiatives aimed at addressing the vaccination needs and gaps among patients with immune-mediated inflammatory conditions. Priority is given to projects that address patients who are part of a medically underserved population.
Closing date: 12 July 2021
Research grants - Merck
Merck invites applications for its research grants. These support innovative scientific research in challenging areas of future importance.
Grants are available in the following focus topics:
•drug discovery - three grants worth up to €350,000 each per year for three years, with the option of extension;
•real-time testing and sensors – grants worth between €100,000 and €500,000 each per year for two years, with the option of extension;
•nanoparticle for nucleic acid delivery – grants worth between €100,000 and €300,000 each per year for two years, with the option of extension;
•digital innovation in biopharmaceutical R&D – three grants worth between €40,000 and €100,000 each for one year, with the option of extension;
•bioelectronics – one grant worth €150,000 per year for three years;
•sustainability – grants to be negotiated on a case by case basis;
•cell culture media recycling for cultured meat – grants to be negotiated on a case by case basis;
•organoids – grants to be negotiated on a case by case basis.
Closing date: 31 Aug 2021
Research and networking grant - European Society for Paediatric Gastroenterology, Hepatology and Nutrition
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition invites proposals for its research and networking grant. These enable members to undertake research activities and network among centres at an international level. Activities may include interactive educational events and clinical networks. Proposals relevant to the society’s activities, such as the validation of guidelines, or clinical networks for testing treatment regimes or disease management, are encouraged.
Closing date: 31 July 2021
Awards for innovating and inspiring science - Nature
Nature, in collaboration with The Estée Lauder Companies, invites applications for its awards for innovating and inspiring science. These recognise female scientists and those involved in projects encouraging women to become more engaged in STEM subjects. The following awards are available:
•scientific achievement award, which early-career researchers, who self-identify as women, transwomen, genderqueer or non-binary and are within 10 years of obtaining their PhD or other doctorate degree, for their contributions to scientific discovery and for displaying potential for developing and leading an independent research group;
•science outreach award, which recognises an individual, group or organisation from across academia, education, organisation and corporate entities who have set up or run initiatives that support girls and young women in studying, engaging with and enjoying science.
Closing date: 20 June 2021
Roger De Spoelberch prize - Roger De Spoelberch Foundation
The Roger De Spoelberch Foundation invites nominations for the Roger De Spoelberch prize. This recognises a clinical and basic scientific research project within the field of neurodegenerative diseases and psychiatric disorders.
Applicants must hold a PhD and be under the age of 55 when the application is submitted. They must be nominated by a person who is duly qualified to assess the value of the candidate’s work. Previous prize winners are not eligible.
Closing date: 30 June 2021
Federal Funding agencies
Duchenne Muscular Dystrophy Research Program (DMDRP)- Department of Defense, US
All applications for the FY21 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on primary pathology of DMD. Eligible therapeutic strategies include gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. Therapies that will be efficacious across the life span, particularly in adolescents and adults, are encouraged.
Studies proposed under this award may include:
- Optimized delivery to affected tissues, including specific targeting to skeletal muscle, heart, and brain (e.g., ligand-assisted delivery, tissue-specific promoters, nanoparticles, alternative vectors, identification of biological barriers to delivery)
- Strategies to overcome preexisting immunity and to facilitate repeat administration of biologic therapies (e.g., immune system modulation, vector modification)
- Therapeutics targeted to muscle stem cells
- Cell-based therapies, including but not limited to, selection of novel cell types, expansion, cell delivery and homing, differentiation, and integration
- Research that will inform and improve therapy in older individuals, including dosing challenges, genetic-based therapies, tissue environments, and other factors that may compromise delivery and efficacy in this patient group
- Therapies addressing secondary pathologies of DMD to the extent that they augment therapies directed at primary disease mechanisms
- Discovery and validation of novel targets, including genetic modifiers and factors that determine the selective vulnerability/resistance of individual muscles, especially in humans
- Validation of novel small animal models that better recapitulate the human pathophysiology.
The anticipated direct costs budgeted for the entire period of performance for an FY21 DMDRP Idea Development Award will not exceed $350,000.
All applications for the FY21 DMDRP Translational Research Award must address at least one of the following Focus Areas:
• Translational and clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve care and quality of life in areas such as:
- Cognitive function, Cardiac, Endocrinology (including bone health and growth), Skeletal muscle
- Assessment of clinical trial tools and outcome measures such as:
- Discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers, including potential surrogate markers,
- Novel clinical outcome assessment,
- Patient-centered outcomes (e.g., quality of life, activities of daily living)
- Secondary data analysis that helps to address clinical research tool validation and/or to understand natural history
- Extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (such as optimizing delivery to target tissues, including drug exposure, independent replication, and comparative studies).
The anticipated direct costs budgeted for the entire period of performance for an FY21 DMDRP Translational Research Award will not exceed $1.3M.
Closing date: 11 August, 2021 (Pre-Application), December 1, 2021 (Full Proposal).
Funding Opportunity Number: W81XWH-21-DMDRP-IDA (Idea Development Award), W81XWH-21-DMDRP-TRA (Translational Research Award)
Neurotoxin Exposure Treatment Parkinson’s (NETP) Research Program - Department of Defense, US
The program name Neurotoxin Exposure Treatment Parkinson’s highlights the program’s research areas.
- Neurotoxin - Synthetic or naturally occurring substances that damage, destroy, or impair the functioning of the central and/or peripheral nervous system. They include both manmade substances (fuel, pesticides, solvents, etc.) and naturally occurring toxins (high concentrations of oxygen radicals, beta amyloid, etc.).
- Exposure - Anything from deployment, environmental, or occupational exposures that causes neurodegeneration.
- Treatment - The desired long-term outcome of research funded by the NETP Program.
- Parkinson’s - A neurodegenerative disease whose risk increases from neurotoxin exposures.
The vision of the NETP Program is to increase the understanding of Parkinson’s disease (PD) and to develop treatments towards a cure.
The mission of the NETP Program is to support Parkinson’s research investigating the underlying biologic mechanisms and therapeutic interventions of neurodegenerative effects caused by deployment, environmental, and occupational exposures.
The long-term NETP Program Strategic Goals within the context of the program’s mission are:
- Determine the biologic mechanisms of neurodegeneration in PD.
- Delineate how deployment, environmental, and occupational exposures in combination with gene - environment interactions impact the development and progression of PD.
- Understand the mechanisms of the cognitive, psychiatric, and other non-motor symptoms of PD.
- Determine how circuitry and synaptic mechanisms of PD, dopamine refractory motor symptoms, and treatment-associated dystonia influence PD progression.
- Identify the biological mechanisms of impact from exercise and other lifestyle modifications on neurodegeneration in PD.
Closing date: 8 September, 2021 (Pre-Application), September 29, 2021 (Full Proposal).
Funding Opportunity Number: W81XWH-21-NETP-EIRA (Early Investigator Research Award),
W81XWH-21-NETP-IIRA (Investigator-Initiated Research Award),
W81XWH-21-NETP-SIA (Synergistic Idea Award).
Clinical consortium award, Prostate Cancer Research Programme (PCRP), Department of Defense, US
The US Department of Defense, under the prostate cancer research programme, invites applications for its clinical consortium award. This provides the support to develop and enhance collaborations and resources necessary for a network of organisations to rapidly execute phase II or phase II-linked phase I (phase I/II) prostate cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer, especially as pertaining to the programme overarching challenges, which are the following:
•improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer;
•develop treatments that improve outcomes for men with lethal prostate cancer;
•advance health equity and reduce disparities in prostate cancer;
•define the biology of lethal prostate cancer to reduce death.
Organisation worldwide may apply. PIs must be independent investigators with a faculty-level appointment.
The total budget is USD 7.68 million to fund one coordinating center and ten clinical research site clinical consortium awards for an initial one year period. The expected period of performance is four years. The four year budget is up to USD 7.2m for the coordinating center and up to USD 1.2m for clinical research sites with a total budget of USD 30.72m.
Closing date: Pre-proposals due by 5pm ET, 2 September; applications due by 11.59 ET, 23 September 2021.
Funding Opportunity Number: W81XWH-21-PCRP-CCA
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01, R21 Clinical Trial Not Allowed), NIH
This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged.
Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for R01 (RFA-DA-22-007)-. Exploratory and high-risk research projects should consider applying to the companion R21 announcement RFA-DA-22-005.
Closing date: October 14, 2021, by 5:00 PM local time of applicant organization. Letter of Intent Due Date: 30 days prior to the application due date.
Global research award, American Society of Hematology, US
The ASH Global Research Award was designed to support future international scientific leaders, increase hematology capacity, and nurture global collaboration. The award is intended to support hematologists between completion of training and the establishment of their independent careers.
The Global Research Award promises to be accessible to individuals across geographical regions. Proposals will be categorized by home country and classification of country using the United Nations Human Development Index; and applicants will only compete with those in their same classification.
The award length may vary from six months to three years, depending on the proposed project need. The award amount is also intended to be flexible. The amount requested in each application will be assessed to determine whether it is appropriate for the project and for the costs of the region. Payments are made in equal quarterly amounts throughout the award.
- For projects of one year or less, the applicant may request up to $100,000.
- For projects of more than one year, the applicant may request up to $150,000.
Closing date: August 31, 2021 (LOI), April 15, 2022 (Application Deadline for Invited Applicants).
Lewis Rudin glaucoma prize, Association for Research in vision and Ophthalmology, US
The Lewis Rudin Glaucoma Prize provides a $30,000 award in recognition of an outstanding scholarly article on glaucoma published in a peer-reviewed journal during the previous calendar year.
The intent of the Lewis Rudin Glaucoma Prize is to recognize and encourage exemplary scholarly research in the field of glaucoma. Lewis Rudin was a prominent real estate developer in New York City. The award is funded by the May and Samuel Rudin Family Foundation with support of his brother Jack Rudin.
The Lewis Rudin Glaucoma Prize was established in 1995 through the New York Academy of Medicine and has become a prestigious award within the glaucoma and ophthalmology communities. The Lewis Rudin Glaucoma Prize was transferred to the ARVO Foundation in 2019.
Closing date: Sept. 1, 2021.
Benson clinical research fellowship, Guillain-Barre Syndrome/Chronic Inflammatory Demyelinating Polyneuropathy Foundation, US
The Benson Fellowship is a three-year fellowship that provides an opportunity for talented scientists to engage in peripheral nerve of study.
The aim of the scheme is to provide funds (up to $150k per year for three years) to enable clinicians or non-clinical scientists in training or having recently completed training to engage in a substantial research project in the field of inflammatory neuropathy at a Centre or Centers of Excellence or an Institution approved by the committee. Preference will be given to candidates who intend to pursue a long-term career in this field.
Applicants should obtain application forms by emailing Lori Basiege at firstname.lastname@example.org.
Closing date: Letters of intent due August 1, Full Application (Invite only) due October 1*, Announcement of Aware December 1, First Installment payout to Awardee on January 1
*Finalists in the Benson Fellowship application that are not chosen for the Fellowship may rework their application for the Discovery Award and submit a full application (by December 1) without a letter of intent